fbpx Is there ROOM for improvement? Development and outcomes of the Routine Opioid Outcome Monitoring study | NDARC - National Drug and Alcohol Research Centre

Is there ROOM for improvement? Development and outcomes of the Routine Opioid Outcome Monitoring study

Associate Professor Suzanne Nielsen
Author: Associate Professor Suzanne Nielsen

Resource Type: NDARC Seminars

Associate Professor Suzanne Nielsen presented at the 2020 NDARC Webinar Series on Thursday, 24 September 2020.

This seminar provides an overview of the development of the Routine Opioid Outcome Monitoring Tool, and shares findings from a pilot implementation effectiveness study conducted with 23 pharmacies from New South Wales and Victoria.

The seminar describes the development of a brief 'Routine Opioid Outcome Monitoring’ or ROOM tool to monitor for emerging problems with prescribed opioids. The seminar also presents findings from a pilot study where the implementation of the tool into practice in community pharmacies in Victoria and New South Wales. The seminar describes how implementation science principles were used to inform the study design, and discuss outcomes from the pilot study.

Speaker bio:

Associate Professor Suzanne Nielsen is the Deputy Director of the Monash Addiction Research Centre at Monash University.

A/Prof Nielsen has published over 125 scientific papers and given over 170 national and international conference presentations in the area of addiction research.

She is a current NHMRC Career Development Fellow, and has previously received an NHMRC Translating Research Into Practice Fellowship and NHMRC Early Career Researcher Fellowship. Her current research focuses on understanding how to improve identification and treatment of prescription opioid use disorder, with the aim of reducing harms with prescribed opioid use. She is also conducting research monitoring for the emergency of novel synthetic opioids, overdose prevention with naloxone, and studying the implementation of prescription drug monitoring and the impact of other policy-level interventions to reduce harm with prescription drugs.